74 Result(s)

Article

Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase

Fosnetupitant is a novel neurokinin 1 receptor antagonist (NK₁RA) with favorable antiemetic efficacy in patients receiving emetogenic chemotherapy. This study assessed the efficacy of fosnetupitant in combination...

Naoki Inui, Yukihiro Toi, Yasuto Yoneshima, Masahiro Morise… in Advances in Therapy (2023)

Article

Findings of virtual bronchoscopic navigation can predict the diagnostic rate of primary lung cancer by bronchoscopy in patients with peripheral lung lesions

Despite being minimally invasive, bronchoscopy does not always result in pathological specimens being obtained. Therefore, we investigated whether virtual bronchoscopic navigation (VBN) findings were associate...

Atsushi Kitamura, Yutaka Tomishima, Ryosuke Imai, Naoki Nishimura… in BMC Pulmonary Medicine (2022)

Article

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)

We describe the results of an exploratory analysis performed on the first head-to-head study (JapicCTI-194611) comparing two different intravenous (IV) neurokinin 1 (NK₁) receptor antagonists, fosnetupitant and f...

Akito Hata, Yoshimasa Shiraishi, Naoki Inui, Morihito Okada… in Oncology and Therapy (2022)

Article

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR...

Makoto Nishio, Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida… in Investigational New Drugs (2019)

Article

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced n...

Shunichi Sugawara, Kazuhiko Nakagawa… in International Journal of Clinical Oncology (2019)

Article

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Background This study evaluated the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of single and multiple doses of nivolumab in Japanese patients with malig...

Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada… in Investigational New Drugs (2017)

Article

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Noboru Yamamoto, Koichi Goto, Makoto Nishio… in International Journal of Clinical Oncology (2017)

Article

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

In Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was demonstrated in the phase II JO22903 trial, which reported a me...

Noboru Yamamoto, Koichi Goto, Makoto Nishio… in International Journal of Clinical Oncology (2017)

Article

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors

This phase 1 study aimed to assess the tolerability, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of lenvatinib capsules in Japanese patients with solid tumors when administered or...

Shinji Nakamichi, Hiroshi Nokihara, Noboru Yamamoto… in Cancer Chemotherapy and Pharmacology (2015)

Article

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)

Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib...

Hidenori Mizugaki, Noboru Yamamoto… in Cancer Chemotherapy and Pharmacology (2015)

Article

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Background Ipilimumab is an antibody that targets the cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor response. Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin ...

Hidehito Horinouchi, Noboru Yamamoto, Yutaka Fujiwara… in Investigational New Drugs (2015)